Ecosinoids Flashcards
Alprostadil (impotence and erectile dysfunction)
Prostaglandin
PGE1
Alprostadil (impotence and erectile dysfunction)
Site of action
corpus cavernosum smooth muscle
Alprostadil (impotence and erectile dysfunction)
Mechanism of Action
PGE1 analog thatworks via the EP2/4 receptors to increase cAMP which relaxes trabecular smooth muscle and dilates cavernous arteries leading to entrapment of blood
Alprostadil (impotence and erectile dysfunction)
Receptor
EP2 Receptor
PGE1 works on EP2 receptor
Alprostadil (impotence and erectile dysfunction)
Major adverse effect
priapism, erection lasting over 6 hours
Two therapuetic uses of Alprostadil
- Impotence and Erectile Dysfunction when PGE1 acts on EP2 receptor on corpus cavernosum smooth muscle causing an increase in cAMP
- Temporary Maintenance of patent ductus arteriosus when PGE1 acts on EP2 receptor on ductus arteriosus smooth muscle leading to increase in cAMP
Alprostadil (maintenance of patent ductus arteriosus)
Prostaglandin
PGE1
Alprostadil (maintenance of patent ductus arteriosus)
Site of Action
ductus arteriosus smooth muscle
Alprostadil (maintenance of patent ductus arteriosus)
Mechanism of Action
PGE1 analog that increases cAMP via EP2 receptor which relaxes ductus arteriosus smooth muscle
Alprostadil (maintenance of patent ductus arteriosus)
Adverse effect
apnea
Two therapeutic uses of Bimatoprost
- glaucoma
2. Eyelash hypotrichosis
Bimatoprost (glaucoma) prostaglandin
Prostamide F2a
Bimatoprost (glaucoma) Site of action
trabecular and uveoscleral aqueous humor outflow pathways
Bimatoprost (glaucoma) Mechanism of action
stimulation of specific Prostamide F2a receptor resulting in changes in genes that remodel cells to increase drainage
Bimatoprost (glaucoma) major adverse effect
increase length and number of eyelashes
Bimatoprost (eyelash hypotrichosis) Prostaglandin
Prostamide F2a
Bimatoprost (eyelash hypotrchosis) Site of action
hair follicles of eye
Bimatoprost (eyelash hypotrichosis) Mechanism of action
Stimulation of specific Prostamide F2a receptor causing increase in anagen phase of hair cycle
Two therapeutic uses for Carboprost
- Pregnancy termination
2. To control postpartum hemorrhage
Carboprost (pregnancy termination) Prostaglandin
PGF2a
Carboprost (pregnancy termination) Site of action
uterine smooth muscle
Carboprost (pregnancy termination) mechanism of action
increase in Ca via FP receptor causing uterine contraction
Carboprost (pregnancy termination) Major adverse effect
uterine rupture
Major adverse effect of bimatoprost (eyelash hypotrichosis)
eye redness, itching
dinoprostone therapeutic functions
- cervical ripening in pregnancy
2. early pregnancy termination
dinoprostone (cervical ripening in pregnancy) prostaglandin
PGE2
dinoprostone (cervical ripening in pregnancy) Site of action
cervix
dinoprostone (cervical ripening in pregnancy) Mechanism of action
- activation of collagenase via EP4 receptor which increases cAMP
- relaxes cervical smooth muscle
dinoprostone (cervical ripening in pregnancy) major adverse effect
uterine rupture
dinoprostone (early pregnancy termination) prostaglandin
PGE2
dinoprostone (early pregnancy termination) Site of action
uterine smooth muscle
dinoprostone (early pregnancy termination) Mechanism of action
EP1 mediated increase in Ca
OR
EP3 mediated decrease in cAMP
causes uterine contractions
dinoprostone (early pregnancy termination) Major adverse effect
uterine rupture
Epoprostenol protaglandin
PGI2
Epoprostenol site of action
Pulmonary artery smooth muscle
Epoprostenol Mechanism of action
increase in cAMP via IP receptor which dilates the pulmonary artery vascular smooth muscle
Epoprostenol major adverse effect
GI related and potential drug interations with other hypertensive therapy or anti-platelt therapy
Epoprostenol therapeutic use
idiopathic pulmonary arterial hypertension
misoprostol prostaglandin
PGE1
misoprostol site of action
parietal cell
misoprostol Mechnaism of action
PGE1 analog that suppresses gastric acid secretion via decrease in cAMP via EP3 receptor